30 newly listed drugs are quickly listed on the Internet through the "green channel"!

On January 13, Shaanxi released relevant information on newly approved drugs, and publicized the information on newly approved drugs declared in December.
A total of 30 drugs will be clinically implemented through the green procurement channel
.
A number of large varieties will usher in a new competitive landscape.
Three companies, Baiji, TOT BIOPHARM, and BEIDA PHARMACEUTICAL, have officially joined the competition for the bevacizumab market, and KELUN and BEIMEY PHARMACEUTICAL will challenge Dongguang Sunshine.

.
New drugs from Qilu, Sanofi, and Zai Lab will also enter the market quickly
.
Baiji, Dongyao and Betta join the bevacizumab market competition.
Newly approved drugs will be listed in two ways: "price-limited listing" and "direct listing"
.
The current lowest online (bid-winning) price in the designated 10 provinces (cities), including Beijing, Jiangsu, Zhejiang, Shandong, etc.
, is used as the limit price, and after publicity, it will be included in the "Limited Price Listing Catalog"
.
If the price of 10 provinces (cities) is not specified, it will be included in the "direct online listing"
.
It is worth noting that the bevacizumab variety has welcomed three more companies, namely BeiGene (Bio-Tech is responsible for the production), Dong Yao Pharmaceutical and Betta Pharmaceuticals, and the competition is about to become fierce
.
Among them, BeiGene's bevacizumab is listed on the Internet in a price-limited way.
The listed price of 400mg/16ml is 3,316 yuan, and the price of 100mg/4mL is 1,147 yuan; Dong Yao Pharmaceutical and The varieties of Betta Pharmaceuticals are directly linked to the Internet, which also means that Baekje has more than 10 provinces and cities listed on the Internet, while the last two are not listed in the designated 10 provinces and cities, and Baekje may be ahead
.
Bevacizumab injection is widely used in the treatment of various malignant tumors, and it is the most competitive biosimilar drug variety.
There are already 9 domestic products competing on the same stage
.
In addition to Roche's original research drugs, there are also 8 biosimilars from Qilu Pharmaceuticals, Innovent Bio, Hengrui Medicine, Boan Bio, Bio-Tech, Betta Bio, Dong Yao Pharmaceutical and Henlius
.
In addition, Chia Tai Tianqing has also submitted a listing application, and the products of 9 other companies are in the clinical phase III
.
Bevacizumab has attracted so many companies to enter the market, which is not unrelated to its broad market prospects and potential space for drug combination
.
According to data from Minet.
com, in recent years, the sales of terminal bevacizumab injection in China's public medical institutions have grown rapidly, breaking the 4 billion yuan mark in 2020, and increasing by more than 80% year-on-year in the first half of 2021, with a sales scale of more than 3 billion yuan.

.
With the development of domestic pharmaceutical companies, the market share of Roche's bevacizumab injection has rapidly declined, falling below 40% from the exclusive market in 2018 to the first half of 2021
.
Qilu Pharma's bevacizumab injection was approved in 2019, the first in China, with a market share of less than 1% in the year it was launched
.
At the same time, in the first three quarters of 2021, the sales of chemical drugs in public hospitals in key cities, Qilu Pharmaceutical's bevacizumab injection, performed well with a growth rate of more than 200%
.
According to the Frost & Sullivan report, the market size of bevacizumab in China will increase to 6.
4 billion yuan in 2023 and 9.
9 billion yuan in 2030, with a very broad prospect
.
In the future, the market competition for this product will also be more intense
.
Some companies of oseltamivir have terminated the research and development of another major variety, and two companies have also entered the market, one is oseltamivir phosphate capsules from Sichuan Kelun, and the other is oseltamivir phosphate dry mix from Shenzhen Beimei Pharmaceutical Co.
, Ltd.
Suspension, these two drugs are directly linked to the net
.
According to data from Minet.
com, in 2019, the total sales of oseltamivir in Chinese public medical institutions and physical pharmacies in Chinese cities exceeded 6.
5 billion yuan
.
Affected by the new crown pneumonia epidemic, the public's awareness of protection has been improved, the spread of influenza has decreased, and the flow of people in hospitals has dropped significantly.
The sales of oseltamivir have fallen sharply
.
In 2020, the total sales of oseltamivir in Chinese public medical institutions and Chinese urban physical pharmacy terminals will exceed 3 billion yuan
.
Continuing to decline in 2021, the 2021 semi-annual report released by Sunshine Pharmaceuticals, which occupies over 90% of the oseltamivir market, shows that Kewei (oseltamivir) sales revenue was 53.
6 million yuan, a decrease of 97.
3% from the same period last year
.
In this regard, HEC also chose to sell HEC Pharmaceuticals and divest its pharmaceutical business.

.
In the market, there are 5 manufacturers of oseltamivir capsules, namely Roche, Yichang Dongguang Changjiang Pharmaceutical Co.
, Ltd.
, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Borui Pharmaceutical Co.
, Ltd.
, and Shanghai Zhongxi Sunwei Pharmaceutical Co.
, Ltd.
There are only granule manufacturers in Yichang.
1 company of Dongguang Changjiang Pharmaceutical Co.
,
Ltd.
In addition, more than ten companies such as oseltamivir phosphate and Yangzijiang, Qilu Pharmaceutical and other companies have submitted their listing applications for review and approval, and the competition is quite fierce
.
However, some companies have opted out
.
Not long ago, Ziluangong, a pharmaceutical company listed on the Beijing Stock Exchange, terminated the follow-up development of oseltamivir phosphate dry suspension
.
As of the end of 2020, the development expenditure of oseltamivir phosphate dry suspension reached 2.
06 million yuan
.
Due to the change of policy, it needs to be re-developed, the research and development time is long and the follow-up investment is large, so the research and development is terminated
.
In addition, Qilu Pharmaceutical's recombinant human follicle-stimulating hormone for injection, Sanofi's dupilimumab injection and Zai Lab's omacycline tosylate have also attracted market attention
.
At the end of last year, Qilu Pharmaceutical's recombinant human follicle-stimulating hormone for injection was approved for marketing
.
According to data from Minet.
com, in recent years, the sales of recombinant human follicle-stimulating hormone injections in Chinese public medical institutions have exceeded 1 billion yuan, with a year-on-year increase of 62.
91% in the first half of 2021
.
Qilu Pharmaceutical also stated that recombinant human follicle-stimulating hormone for injection is a blockbuster product that took 11 years of scientific research
.
Dupilumab, as the world's first approved targeted biologic for the treatment of moderate to severe atopic dermatitis, has global sales of US$4.
3 billion in the first three quarters of 2021, with a year-on-year increase of 55% in the third quarter
.
The domestic market is also growing rapidly
.
As for the promotion of omacycline tosylate, Zai Ding chose to join hands with Hisun
.
It is understood that Hisun has been deeply engaged in the field of anti-infection for many years, and ranks among the top three in the anti-infection sales market.
The cooperation between the two companies is expected to help omacycline tosylate become the first-line choice for the treatment of community-acquired pneumonia (CAP).

.
R&D investment is soaring, and Hengrui, Qilu, and CSPC are competing for the first place.
Nowadays, the competition among enterprises is escalating around large varieties, especially among large pharmaceutical companies
.
This is not unrelated to the fact that Hengrui, Qilu, CSPC and other large pharmaceutical companies have increased investment in R&D and accelerated the transition from "combination of imitation and innovation" to "combination of innovation and imitation"
.
According to the data, it is expected that in 2021, the R&D investment of Hengrui, Qilu and CSPC will reach a new high, with a total of more than 10 billion yuan
.
In recent years, Hengrui Pharmaceutical's R&D investment has maintained rapid growth year after year, reaching nearly 5 billion yuan in 2020 and more than 4 billion yuan in the first three quarters of 2021.
R&D investment accounts for more than 20% of revenue; Qilu Pharmaceutical's R&D investment accounts for sales revenue The proportion continued to rise, increasing to 8% to 10%
.
In 2020, the company's R&D investment was 2.
65 billion yuan, and it is expected to reach 3.
9 billion yuan in 2021; in 2020, CSPC's investment in R&D innovation hit a new high, with a total investment of nearly 3 billion yuan in research and development
.
In the first three quarters of 2021, CSPC's R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With increasing investment in R&D, companies are also reaping innovative results one after another
.
In addition to the 10 innovative drugs already on the market, Hengrui currently has more than 50 innovative drugs under clinical development, and more than 240 clinical trials are being conducted at home and abroad
.
At present, Qilu Pharmaceutical has 23 Class 1 new drugs in the pipeline of clinical application and above, including 17 innovative macromolecular drugs, which are deployed in the fields of monoclonal antibody, double antibody and ADC
.
CSPC has about 300 products under development, of which about 100 are innovative drug products, and more than 60 new products are expected to be launched in the next three years
.
It is foreseeable that in the future, competition among enterprises will extend from common varieties to innovative drugs, bringing more treatment options to the clinic
.
Shaanxi complies with the announcement form of newly approved drugs